Tumor-associated glycan antigens (TAGA)

Tumor-associated glycan antigens (TAGAs) are carbohydrate structures found on the surface of cancer cells that result from aberrant glycosylation processes, such as premature termination of glycan chains or increased sialylation (Pinho & Reis, 2015, Nature Reviews Cancer). These antigens, which include structures like Tn, Sialyl-Tn (STn), Lewis antigens, and gangliosides (e.g., GD2, GM2), play critical roles in tumor biology by promoting cell migration, invasion, and immune system evasion (Munkley & Elliott, 2016, International Journal of Molecular Sciences). Because TAGAs are often overexpressed or uniquely presented on malignant cells compared to healthy tissues, they serve as highly specific targets for therapeutic intervention, including monoclonal antibodies, CAR-T cells, and cancer vaccines (Zhou & Hakomori, 2011, FEBS Letters). In clinical practice, TAGAs are widely utilized as diagnostic and prognostic biomarkers, such as CA19-9 and CA125, which monitor disease progression and treatment response (Varki et al., 2015, Essentials of Glycobiology). Therapeutic strategies targeting these glycans aim to disrupt the physical and signaling advantages they provide to the tumor or to direct the host's immune system to destroy glycan-bearing cancer cells. However, challenges remain due to the inherently low immunogenicity of carbohydrates and the potential for off-target effects if the glycan is also expressed at lower levels on vital normal tissues (Büll et al., 2014, Cancer Research).

Other names

Tumor-associated carbohydrate antigensTACACancer-associated glycansAberrant glycosylation antigensTumor-specific glycans

Monoclonal antibodies target TAGAs to induce antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC); glycan-based vaccines stimulate the production of endogenous antibodies against tumor cells; glycomimetics inhibit glycan-binding proteins (lectins) to prevent cell adhesion and metastasis.